Global and China Neuromyelitis Optica Drug Market Size, Status and Forecast 2021-2027

Publisher Name :
Date: 10-Sep-2021
No. of pages: 108
Inquire Before Buying

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

Market Analysis and Insights: Global Neuromyelitis Optica Drug Market

The global Neuromyelitis Optica Drug market size is projected to reach US$ 56 million by 2027, from US$ 43 million in 2020, at a CAGR of 3.0% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuromyelitis Optica Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuromyelitis Optica Drug market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuromyelitis Optica Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuromyelitis Optica Drug market.

Global Neuromyelitis Optica Drug Scope and Market Size

Neuromyelitis Optica Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuromyelitis Optica Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

- Glucocorticoids

- Immunotherapies

- Others

Segment by Application

- Acute Attack

- Remission Prophylactic Treatment

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- - Nordic

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

By Company

- Pfizer

- Fresenius

- Teva

- Sandoz

- Intas

- Gyjtrs

- NANG KUANG

- Tianjin Kingyork

- Baxter

- CSL

- Grifols

- Octapharma

- CBOP

Global and China Neuromyelitis Optica Drug Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2016-2027)
2.2 Neuromyelitis Optica Drug Growth Trends by Regions
2.2.1 Neuromyelitis Optica Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuromyelitis Optica Drug Historic Market Share by Regions (2016-2021)
2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Regions (2022-2027)
2.3 Neuromyelitis Optica Drug Industry Dynamic
2.3.1 Neuromyelitis Optica Drug Market Trends
2.3.2 Neuromyelitis Optica Drug Market Drivers
2.3.3 Neuromyelitis Optica Drug Market Challenges
2.3.4 Neuromyelitis Optica Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Drug Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2016-2021)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2016-2021)
3.2 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Drug Revenue
3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2020
3.5 Neuromyelitis Optica Drug Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Drug Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Drug Breakdown Data by Type
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2016-2021)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2022-2027)
5 Neuromyelitis Optica Drug Breakdown Data by Application
5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2016-2021)
5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size (2016-2027)
6.2 North America Neuromyelitis Optica Drug Market Size by Type
6.2.1 North America Neuromyelitis Optica Drug Market Size by Type (2016-2021)
6.2.2 North America Neuromyelitis Optica Drug Market Size by Type (2022-2027)
6.2.3 North America Neuromyelitis Optica Drug Market Size by Type (2016-2027)
6.3 North America Neuromyelitis Optica Drug Market Size by Application
6.3.1 North America Neuromyelitis Optica Drug Market Size by Application (2016-2021)
6.3.2 North America Neuromyelitis Optica Drug Market Size by Application (2022-2027)
6.3.3 North America Neuromyelitis Optica Drug Market Size by Application (2016-2027)
6.4 North America Neuromyelitis Optica Drug Market Size by Country
6.4.1 North America Neuromyelitis Optica Drug Market Size by Country (2016-2021)
6.4.2 North America Neuromyelitis Optica Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Drug Market Size (2016-2027)
7.2 Europe Neuromyelitis Optica Drug Market Size by Type
7.2.1 Europe Neuromyelitis Optica Drug Market Size by Type (2016-2021)
7.2.2 Europe Neuromyelitis Optica Drug Market Size by Type (2022-2027)
7.2.3 Europe Neuromyelitis Optica Drug Market Size by Type (2016-2027)
7.3 Europe Neuromyelitis Optica Drug Market Size by Application
7.3.1 Europe Neuromyelitis Optica Drug Market Size by Application (2016-2021)
7.3.2 Europe Neuromyelitis Optica Drug Market Size by Application (2022-2027)
7.3.3 Europe Neuromyelitis Optica Drug Market Size by Application (2016-2027)
7.4 Europe Neuromyelitis Optica Drug Market Size by Country
7.4.1 Europe Neuromyelitis Optica Drug Market Size by Country (2016-2021)
7.4.2 Europe Neuromyelitis Optica Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2016-2027)
8.2 Asia-Pacific Neuromyelitis Optica Drug Market Size by Type
8.2.1 Asia-Pacific Neuromyelitis Optica Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuromyelitis Optica Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Application
8.3.1 Asia-Pacific Neuromyelitis Optica Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuromyelitis Optica Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region
8.4.1 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size (2016-2027)
9.2 Latin America Neuromyelitis Optica Drug Market Size by Type
9.2.1 Latin America Neuromyelitis Optica Drug Market Size by Type (2016-2021)
9.2.2 Latin America Neuromyelitis Optica Drug Market Size by Type (2022-2027)
9.2.3 Latin America Neuromyelitis Optica Drug Market Size by Type (2016-2027)
9.3 Latin America Neuromyelitis Optica Drug Market Size by Application
9.3.1 Latin America Neuromyelitis Optica Drug Market Size by Application (2016-2021)
9.3.2 Latin America Neuromyelitis Optica Drug Market Size by Application (2022-2027)
9.3.3 Latin America Neuromyelitis Optica Drug Market Size by Application (2016-2027)
9.4 Latin America Neuromyelitis Optica Drug Market Size by Country
9.4.1 Latin America Neuromyelitis Optica Drug Market Size by Country (2016-2021)
9.4.2 Latin America Neuromyelitis Optica Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2016-2027)
10.2 Middle East & Africa Neuromyelitis Optica Drug Market Size by Type
10.2.1 Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Application
10.3.1 Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country
10.4.1 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuromyelitis Optica Drug Introduction
11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Fresenius
11.2.1 Fresenius Company Details
11.2.2 Fresenius Business Overview
11.2.3 Fresenius Neuromyelitis Optica Drug Introduction
11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.2.5 Fresenius Recent Development
11.3 Teva
11.3.1 Teva Company Details
11.3.2 Teva Business Overview
11.3.3 Teva Neuromyelitis Optica Drug Introduction
11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.3.5 Teva Recent Development
11.4 Sandoz
11.4.1 Sandoz Company Details
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Neuromyelitis Optica Drug Introduction
11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.4.5 Sandoz Recent Development
11.5 Intas
11.5.1 Intas Company Details
11.5.2 Intas Business Overview
11.5.3 Intas Neuromyelitis Optica Drug Introduction
11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.5.5 Intas Recent Development
11.6 Gyjtrs
11.6.1 Gyjtrs Company Details
11.6.2 Gyjtrs Business Overview
11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.6.5 Gyjtrs Recent Development
11.7 NANG KUANG
11.7.1 NANG KUANG Company Details
11.7.2 NANG KUANG Business Overview
11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.7.5 NANG KUANG Recent Development
11.8 Tianjin Kingyork
11.8.1 Tianjin Kingyork Company Details
11.8.2 Tianjin Kingyork Business Overview
11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.8.5 Tianjin Kingyork Recent Development
11.9 Baxter
11.9.1 Baxter Company Details
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Drug Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Details
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Drug Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Details
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Drug Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Details
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Drug Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.12.5 Octapharma Recent Development
11.13 CBOP
11.13.1 CBOP Company Details
11.13.2 CBOP Business Overview
11.13.3 CBOP Neuromyelitis Optica Drug Introduction
11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2016-2021)
11.13.5 CBOP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Glucocorticoids
Table 3. Key Players of Immunotherapies
Table 4. Key Players of Others
Table 5. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neuromyelitis Optica Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neuromyelitis Optica Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Neuromyelitis Optica Drug Market Share by Regions (2016-2021)
Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Neuromyelitis Optica Drug Market Share by Regions (2022-2027)
Table 11. Neuromyelitis Optica Drug Market Trends
Table 12. Neuromyelitis Optica Drug Market Drivers
Table 13. Neuromyelitis Optica Drug Market Challenges
Table 14. Neuromyelitis Optica Drug Market Restraints
Table 15. Global Neuromyelitis Optica Drug Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Neuromyelitis Optica Drug Market Share by Players (2016-2021)
Table 17. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Drug as of 2020)
Table 18. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neuromyelitis Optica Drug Product Solution and Service
Table 22. Date of Enter into Neuromyelitis Optica Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuromyelitis Optica Drug Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2016-2021)
Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Neuromyelitis Optica Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2016-2021)
Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Neuromyelitis Optica Drug Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Neuromyelitis Optica Drug Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Neuromyelitis Optica Drug Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Neuromyelitis Optica Drug Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Neuromyelitis Optica Drug Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Neuromyelitis Optica Drug Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Neuromyelitis Optica Drug Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Neuromyelitis Optica Drug Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Neuromyelitis Optica Drug Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Neuromyelitis Optica Drug Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Neuromyelitis Optica Drug Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Neuromyelitis Optica Drug Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Neuromyelitis Optica Drug Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Neuromyelitis Optica Drug Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neuromyelitis Optica Drug Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neuromyelitis Optica Drug Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Neuromyelitis Optica Drug Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Neuromyelitis Optica Drug Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Neuromyelitis Optica Drug Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Neuromyelitis Optica Drug Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Neuromyelitis Optica Drug Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Neuromyelitis Optica Drug Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Neuromyelitis Optica Drug Product
Table 65. Pfizer Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Fresenius Company Details
Table 68. Fresenius Business Overview
Table 69. Fresenius Neuromyelitis Optica Drug Product
Table 70. Fresenius Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 71. Fresenius Recent Development
Table 72. Teva Company Details
Table 73. Teva Business Overview
Table 74. Teva Neuromyelitis Optica Drug Product
Table 75. Teva Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 76. Teva Recent Development
Table 77. Sandoz Company Details
Table 78. Sandoz Business Overview
Table 79. Sandoz Neuromyelitis Optica Drug Product
Table 80. Sandoz Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 81. Sandoz Recent Development
Table 82. Intas Company Details
Table 83. Intas Business Overview
Table 84. Intas Neuromyelitis Optica Drug Product
Table 85. Intas Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 86. Intas Recent Development
Table 87. Gyjtrs Company Details
Table 88. Gyjtrs Business Overview
Table 89. Gyjtrs Neuromyelitis Optica Drug Product
Table 90. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 91. Gyjtrs Recent Development
Table 92. NANG KUANG Company Details
Table 93. NANG KUANG Business Overview
Table 94. NANG KUANG Neuromyelitis Optica Drug Product
Table 95. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 96. NANG KUANG Recent Development
Table 97. Tianjin Kingyork Company Details
Table 98. Tianjin Kingyork Business Overview
Table 99. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 100. Tianjin Kingyork Recent Development
Table 101. Baxter Company Details
Table 102. Baxter Business Overview
Table 103. Baxter Neuromyelitis Optica Drug Product
Table 104. Baxter Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 105. Baxter Recent Development
Table 106. CSL Company Details
Table 107. CSL Business Overview
Table 108. CSL Neuromyelitis Optica Drug Product
Table 109. CSL Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 110. CSL Recent Development
Table 111. Grifols Company Details
Table 112. Grifols Business Overview
Table 113. Grifols Neuromyelitis Optica Drug Product
Table 114. Grifols Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 115. Grifols Recent Development
Table 116. Octapharma Company Details
Table 117. Octapharma Business Overview
Table 118. Octapharma Neuromyelitis Optica Drug Product
Table 119. Octapharma Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 120. Octapharma Recent Development
Table 121. CBOP Company Details
Table 122. CBOP Business Overview
Table 123. CBOP Neuromyelitis Optica Drug Product
Table 124. CBOP Revenue in Neuromyelitis Optica Drug Business (2016-2021) & (US$ Million)
Table 125. CBOP Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuromyelitis Optica Drug Market Share by Type: 2020 VS 2027
Figure 2. Glucocorticoids Features
Figure 3. Immunotherapies Features
Figure 4. Others Features
Figure 5. Global Neuromyelitis Optica Drug Market Share by Application: 2020 VS 2027
Figure 6. Acute Attack Case Studies
Figure 7. Remission Prophylactic Treatment Case Studies
Figure 8. Neuromyelitis Optica Drug Report Years Considered
Figure 9. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Neuromyelitis Optica Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Neuromyelitis Optica Drug Market Share by Regions: 2020 VS 2027
Figure 12. Global Neuromyelitis Optica Drug Market Share by Regions (2022-2027)
Figure 13. Global Neuromyelitis Optica Drug Market Share by Players in 2020
Figure 14. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Drug as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2020
Figure 16. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2016-2021)
Figure 17. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2022-2027)
Figure 18. North America Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Neuromyelitis Optica Drug Market Share by Type (2016-2027)
Figure 20. North America Neuromyelitis Optica Drug Market Share by Application (2016-2027)
Figure 21. North America Neuromyelitis Optica Drug Market Share by Country (2016-2027)
Figure 22. United States Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Neuromyelitis Optica Drug Market Share by Type (2016-2027)
Figure 26. Europe Neuromyelitis Optica Drug Market Share by Application (2016-2027)
Figure 27. Europe Neuromyelitis Optica Drug Market Share by Country (2016-2027)
Figure 28. Germany Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Neuromyelitis Optica Drug Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Neuromyelitis Optica Drug Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Neuromyelitis Optica Drug Market Share by Region (2016-2027)
Figure 38. China Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Neuromyelitis Optica Drug Market Share by Type (2016-2027)
Figure 46. Latin America Neuromyelitis Optica Drug Market Share by Application (2016-2027)
Figure 47. Latin America Neuromyelitis Optica Drug Market Share by Country (2016-2027)
Figure 48. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Neuromyelitis Optica Drug Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Neuromyelitis Optica Drug Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2016-2027)
Figure 54. Turkey Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Neuromyelitis Optica Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 58. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 59. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 60. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 61. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 62. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 63. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 64. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 65. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 66. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 67. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 68. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 69. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
  • Global Narcolepsy Drug Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 80
    According to our LPI (LP Information) latest study, the global Narcolepsy Drug market size was valued at US$ 2715.1 million in 2023. With growing demand in downstream market, the Narcolepsy Drug is forecast to a readjusted size of US$ 5598.9 million by 2030 with a CAGR of 10.9% during review period. The research report highlights the growth potential of the global Narcolepsy Drug market. Narcolepsy Drug are expected to show stable growth in the future market. However, product differentia......
  • Global Epilepsy Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 121
    Market Overview of Global Epilepsy Drugs market: According to our latest research, the global Epilepsy Drugs market looks promising in the next 5 years. As of 2022, the global Epilepsy Drugs market was estimated at USD 4815.92 million, and it's anticipated to reach USD 6053.85 million in 2028, with a CAGR of 3.89% during the forecast years. Anti-epileptic drugs can eliminate or reduce seizures in two ways. One is to affect central neurons to prevent or reduce their pathologic......
  • Global Neuromyelitis Optica Drug Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 107
    According to our LPI (LP Information) latest study, the global Neuromyelitis Optica Drug market size was valued at US$ 46 million in 2023. With growing demand in downstream market, the Neuromyelitis Optica Drug is forecast to a readjusted size of US$ 57 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Neuromyelitis Optica Drug market. Neuromyelitis Optica Drug are expected to show stable growth in the future marke......
  • Migraine Drugs - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 118
    The global Migraine Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Migraine Drugs in various end use industries. The expanding demands from the Hospitals, Clinics, Household Use and Others, are propelling Migraine Drugs market. Sumatriptan, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in......
  • Global Neuromyelitis Optica Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 19-Dec-2023        Price: US 3380 Onwards        Pages: 121
    Market Overview of Global Neuromyelitis Optica Drug market: According to our latest research, the global Neuromyelitis Optica Drug market looks promising in the next 5 years. As of 2022, the global Neuromyelitis Optica Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the glo......
  • Global Narcolepsy Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 126
    Market Overview of Global Narcolepsy Drug market: According to our latest research, the global Narcolepsy Drug market looks promising in the next 5 years. As of 2022, the global Narcolepsy Drug market was estimated at USD 2915.59 million, and it's anticipated to reach USD 5983.81 million in 2028, with a CAGR of 12.73% during the forecast years. Narcolepsy is a neurological disorder characterized by the brain's inability to control sleep/wakefulness cycles. This......
  • Global Edaravone Market Research Report 2023
    Published: 05-Dec-2023        Price: US 2900 Onwards        Pages: 88
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Edaravone market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Mitsubishi Tanabe Pharma - Simcere - Taj Pharmaceuticals Ltd. - Sun Pharmaceutical Industries Ltd. - Unichem Laboratories Ltd - UCB India Ltd - Piram......
  • Global Ethoxyquin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Ethoxyquin market: According to our latest research, the global Ethoxyquin market looks promising in the next 5 years. As of 2022, the global Ethoxyquin market was estimated at USD 216.07 million, and it's anticipated to reach USD 303.42 million in 2028, with a CAGR of 5.82% during the forecast years. Ethoxyquin (EQ) is a clear, viscous, light yellow to dark brown liquid, with an unpleasant, mercaptan-like smell, that causes irritation of the skin an......
  • Global Antipsychotic Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Oct-2023        Price: US 3380 Onwards        Pages: 117
    Market Overview of Global Antipsychotic Drugs market: According to our latest research, the global Antipsychotic Drugs market looks promising in the next 5 years. As of 2022, the global Antipsychotic Drugs market was estimated at USD 15363.6 million, and it's anticipated to reach USD 23658.8 million in 2028, with a CAGR of 7.46% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global An......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs